Login to Your Account

GPC Eliminates 46 Positions In New Round Of Job Cuts

By Cormac Sheridan

Wednesday, August 29, 2007
Following its recent failure to obtain accelerated approval from the FDA for its prostate cancer drug satraplatin, GPC Biotech AG has responded by cutting 46 positions at its Princeton, N.J., site, which represents approximately 15 percent of its payroll. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription